Waters stock holds above $410 as investors digest strong Q2 2026 growth and fresh guidance

Waters stock is trading above $410 as investors weigh a triple-digit revenue jump in Q2 2026 against new earnings guidance for the rest of the year.

Waters Corp (US9418481035) stock is trading firmly above the $410 mark as of August 31, 2026, with a recent quote of $414.55 putting the shares within sight of recent highs while investors assess a sharp acceleration in growth and updated guidance for the rest of the year. Per a same-day portfolio update, the stock opened at $414.55 in the latest session, underscoring solid demand after the company delivered strong second quarter 2026 results and set new earnings targets for the coming quarters. For investors, the combination of triple-digit revenue growth and raised guidance has turned Waters into a higher-growth story within the life sciences instruments space.

Q2 2026 results show triple-digit revenue growth

Waters Corp reported its latest quarterly numbers for the second quarter of 2026, and the figures highlight a powerful rebound in demand for its analytical instruments and related services. In its Q2 2026 release, the company posted earnings per share of $3.05, modestly ahead of the consensus estimate of $3.01, demonstrating an ability to translate higher top-line growth into improved profitability. The same document shows revenue of $1.65 billion for the quarter, compared with analyst expectations of $1.62 billion, giving Waters a revenue beat of $30 million for the period. Importantly for growth-focused investors, Q2 2026 revenue was up 113.3% compared with the same quarter of the prior year, turning Waters into a standout grower among established laboratory instruments suppliers.

The margin profile in Q2 2026 also points to improving operational efficiency. According to the earnings summary, Waters achieved a net margin of 3.58% in the quarter and generated a return on equity of 11.27%, metrics that show the business is using its capital base more effectively than in the recent past. With earnings per share rising from $2.95 in the prior-year quarter to $3.05 in Q2 2026, profit increased by $0.10 per share, a gain of 3.4% year over year. When combined with the 113.3% revenue surge, the EPS advance indicates that Waters is not just growing fast but also maintaining discipline around costs and pricing.

Guidance and outlook support a premium valuation

Beyond the strong Q2 2026 print, Waters has given investors clearer visibility into its expected earnings trajectory for the remainder of the year and the upcoming quarter. The company has set its guidance for the third quarter of 2026 at earnings per share between $3.95 and $4.05, signaling that management anticipates another step-up in profitability relative to Q2 2026. That midpoint of $4.00 would represent growth of roughly $0.95 versus the Q2 2026 EPS figure of $3.05, translating into an earnings increase of more than 31% on a sequential basis if delivered.

For the full year 2026, Waters has announced a guidance range of $14.45 to $14.65 in earnings per share. The midpoint of $14.55 sits slightly below the current consensus forecast of $14.56 EPS for fiscal 2026, yet the company’s own range still implies meaningful expansion from the prior year and underscores the sustainability of the current growth phase. With Q2 2026 revenue already up 113.3% year over year and EPS ahead of expectations, the guidance suggests that management believes the demand drivers behind that surge - including increased instrument placements and higher recurring service revenue - will carry through the rest of the year.

From a market perspective, the latest quote of $414.55 as of the most recent trading session implies that investors are willing to pay a premium multiple for Waters’ earnings stream, given the sharply higher top-line growth and the clear forward earnings roadmap. As long as the company continues to deliver against its guidance ranges, the valuation anchored around that price could remain supported, particularly in a global equity environment where investors have been rewarding consistent growth stories in health care and related technology fields.

Core chromatography and mass spectrometry systems underpin growth

A key driver behind Waters Corp’s recent performance is its portfolio of chromatography and mass spectrometry systems, which are widely used in pharmaceutical development, biopharmaceutical quality control, food safety testing, and environmental analysis. One representative product family is the company’s high-performance liquid chromatography platforms, which pair advanced separation technology with integrated software to allow labs to analyze complex mixtures with high precision. These systems often sit at the heart of regulated workflows, making them mission critical for customers and creating a base of recurring revenue from consumables, service, and software updates.

Waters has been complementing these instrument lines with enhanced digital offerings and workflow solutions designed to improve data management and regulatory compliance. As the Q2 2026 financial figures show, those efforts are increasingly translating into higher revenue and improved profitability at scale. For investors, the product story matters because it links the reported revenue and EPS gains back to tangible drivers: growing instrument installed base, higher recurring revenue streams, and expanding addressable markets in biopharma and advanced materials testing.

Stock level holds firm above $410

With Waters Corp listed on the New York Stock Exchange under the ticker WAT, the latest available price of $414.55 in USD as of the recent session situates the stock in a strong technical position, well above many legacy trading ranges from prior years. While intraday fluctuations are a normal feature of trading, the fact that the shares are holding above the $410 threshold in late August 2026 lines up with the fundamental narrative of accelerating growth and solid guidance. For retail investors, the key takeaway is that Waters stock now reflects a combination of robust Q2 2026 results, a clear earnings outlook for Q3 and full-year 2026, and a product portfolio that continues to generate mission-critical demand across regulated industries.

Fact box

Company: Waters Corp Inc.

ISIN: US9418481035

Ticker: WAT

Exchange: New York Stock Exchange

Price (as of August 31, 2026, 9:07 a.m. ET): $414.55 USD

Sector / Industry: Health care - Life sciences tools and services

Index membership: S&P 500